15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics

João Conde; Alfredo Ambrosone; Yulan Hernandez; Furong Tian; Mark McCully; Catherine C. Berry; Pedro Miguel Ribeiro Viana Baptista; Claudia Tortiglione; Jesus M. de la Fuente

doi:10.1016/j.nantod.2015.06.008

15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics

João Conde, Alfredo Ambrosone, Yulan Hernandez, Furong Tian, Mark McCully, Catherine C. Berry, Pedro Miguel Ribeiro Viana Baptista, Claudia Tortiglione, Jesus M. de la Fuente

Research output: Contribution to journal › Literature review › peer-review

70 Citations (Scopus)

Abstract

RNAi has always captivated scientists due to its tremendous power to modulate the phenotype of living organisms. This natural and powerful biological mechanism can now be harnessed to downregulate specific gene expression in diseased cells, opening up endless opportunities. Since most of the conventional siRNA delivery methods are limited by a narrow therapeutic index and significant side and off-target effects, we are now in the dawn of a new age in gene therapy driven by nanotechnology vehicles for RNAi therapeutics. Here, we outlook the "do's and dont's" of the inorganic RNAi nanomaterials developed in the last 15 years and the different strategies employed are compared and scrutinized, offering important suggestions for the next 15. (C) 2015 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	421-450
Number of pages	30
Journal	Nano today
Volume	10
Issue number	4
DOIs	https://doi.org/10.1016/j.nantod.2015.06.008
Publication status	Published - Aug 2015

Keywords

RNAi therapy
siRNA delivery
Inorganic nanoparticles
Targeting
Nanotoxicity
Nanomedicine
MESOPOROUS SILICA NANOPARTICLES
SMALL INTERFERING RNA
COATED GOLD NANOPARTICLES
IRON-OXIDE NANOPARTICLES
OVERCOME DRUG-RESISTANCE
SUPPORTED LIPID-BILAYERS
LEUKEMIA K562 CELLS
DOUBLE-STRANDED-RNA
IN-VIVO
QUANTUM DOTS

Access to Document

10.1016/j.nantod.2015.06.008

Cite this

@article{00f11403db2241548a313a66e5858539,

title = "15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics",

abstract = "RNAi has always captivated scientists due to its tremendous power to modulate the phenotype of living organisms. This natural and powerful biological mechanism can now be harnessed to downregulate specific gene expression in diseased cells, opening up endless opportunities. Since most of the conventional siRNA delivery methods are limited by a narrow therapeutic index and significant side and off-target effects, we are now in the dawn of a new age in gene therapy driven by nanotechnology vehicles for RNAi therapeutics. Here, we outlook the {"}do's and dont's{"} of the inorganic RNAi nanomaterials developed in the last 15 years and the different strategies employed are compared and scrutinized, offering important suggestions for the next 15. (C) 2015 Elsevier Ltd. All rights reserved.",

keywords = "RNAi therapy, siRNA delivery, Inorganic nanoparticles, Targeting, Nanotoxicity, Nanomedicine, MESOPOROUS SILICA NANOPARTICLES, SMALL INTERFERING RNA, COATED GOLD NANOPARTICLES, IRON-OXIDE NANOPARTICLES, OVERCOME DRUG-RESISTANCE, SUPPORTED LIPID-BILAYERS, LEUKEMIA K562 CELLS, DOUBLE-STRANDED-RNA, IN-VIVO, QUANTUM DOTS",

author = "Jo{\~a}o Conde and Alfredo Ambrosone and Yulan Hernandez and Furong Tian and Mark McCully and Berry, {Catherine C.} and Baptista, {Pedro Miguel Ribeiro Viana} and Claudia Tortiglione and {de la Fuente}, {Jesus M.}",

note = "info:eu-repo/grantAgreement/EC/FP7/239931/EU# FP7-PEOPLE-2013-IOF, project no. 626386 SAF2014-54763-C2-2-R Sem PDF conforme despacho.",

year = "2015",

month = aug,

doi = "10.1016/j.nantod.2015.06.008",

language = "English",

volume = "10",

pages = "421--450",

journal = "Nano today",

issn = "1748-0132",

publisher = "ELSEVIER SCI LTD",

number = "4",

}

TY - JOUR

T1 - 15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics

AU - Conde, João

AU - Ambrosone, Alfredo

AU - Hernandez, Yulan

AU - Tian, Furong

AU - McCully, Mark

AU - Berry, Catherine C.

AU - Baptista, Pedro Miguel Ribeiro Viana

AU - Tortiglione, Claudia

AU - de la Fuente, Jesus M.

N1 - info:eu-repo/grantAgreement/EC/FP7/239931/EU# FP7-PEOPLE-2013-IOF, project no. 626386 SAF2014-54763-C2-2-R Sem PDF conforme despacho.

PY - 2015/8

Y1 - 2015/8

N2 - RNAi has always captivated scientists due to its tremendous power to modulate the phenotype of living organisms. This natural and powerful biological mechanism can now be harnessed to downregulate specific gene expression in diseased cells, opening up endless opportunities. Since most of the conventional siRNA delivery methods are limited by a narrow therapeutic index and significant side and off-target effects, we are now in the dawn of a new age in gene therapy driven by nanotechnology vehicles for RNAi therapeutics. Here, we outlook the "do's and dont's" of the inorganic RNAi nanomaterials developed in the last 15 years and the different strategies employed are compared and scrutinized, offering important suggestions for the next 15. (C) 2015 Elsevier Ltd. All rights reserved.

AB - RNAi has always captivated scientists due to its tremendous power to modulate the phenotype of living organisms. This natural and powerful biological mechanism can now be harnessed to downregulate specific gene expression in diseased cells, opening up endless opportunities. Since most of the conventional siRNA delivery methods are limited by a narrow therapeutic index and significant side and off-target effects, we are now in the dawn of a new age in gene therapy driven by nanotechnology vehicles for RNAi therapeutics. Here, we outlook the "do's and dont's" of the inorganic RNAi nanomaterials developed in the last 15 years and the different strategies employed are compared and scrutinized, offering important suggestions for the next 15. (C) 2015 Elsevier Ltd. All rights reserved.

KW - RNAi therapy

KW - siRNA delivery

KW - Inorganic nanoparticles

KW - Targeting

KW - Nanotoxicity

KW - Nanomedicine

KW - MESOPOROUS SILICA NANOPARTICLES

KW - SMALL INTERFERING RNA

KW - COATED GOLD NANOPARTICLES

KW - IRON-OXIDE NANOPARTICLES

KW - OVERCOME DRUG-RESISTANCE

KW - SUPPORTED LIPID-BILAYERS

KW - LEUKEMIA K562 CELLS

KW - DOUBLE-STRANDED-RNA

KW - IN-VIVO

KW - QUANTUM DOTS

U2 - 10.1016/j.nantod.2015.06.008

DO - 10.1016/j.nantod.2015.06.008

M3 - Literature review

SN - 1748-0132

VL - 10

SP - 421

EP - 450

JO - Nano today

JF - Nano today

IS - 4

ER -

15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics

Abstract

Keywords

Access to Document

Fingerprint

Cite this